ARPC1B promotes gastric cancer tumorigenesis via IGF2BP3-mediated stabilization of HK2 mRNA and glycolytic reprogramming.
1/5 보강
[BACKGROUND] Cancer cells improve survival through metabolic reprogramming, predominantly shifting to glycolysis.
APA
Ma J, Wang L, et al. (2026). ARPC1B promotes gastric cancer tumorigenesis via IGF2BP3-mediated stabilization of HK2 mRNA and glycolytic reprogramming.. European journal of medical research. https://doi.org/10.1186/s40001-026-04087-4
MLA
Ma J, et al.. "ARPC1B promotes gastric cancer tumorigenesis via IGF2BP3-mediated stabilization of HK2 mRNA and glycolytic reprogramming.." European journal of medical research, 2026.
PMID
41803983 ↗
Abstract 한글 요약
[BACKGROUND] Cancer cells improve survival through metabolic reprogramming, predominantly shifting to glycolysis. Actin-related protein 2/3 complex subunit 1B (ARPC1B) is abnormally overexpressed in multiple malignancies and significantly associated with the poor prognosis of patients. However, the role of ARPC1B in gastric cancer (GC) remains poorly characterized.
[METHODS] ARPC1B expression in GC and its association with clinicopathological features were assessed using bioinformatics (TCGA, GEPIA), western blotting, and immunohistochemical staining. The functional impact of ARPC1B on glycolysis (ECAR, OCR, glucose uptake, lactate/ATP production) and tumorigenesis (proliferation, migration, invasion, in vivo xenografts) was evaluated following ARPC1B knockdown or overexpression. ARPC1B-IGF2BP3 interaction was validated by co-immunoprecipitation and confocal microscopy. IGF2BP3-dependent stabilization of hexokinase 2 (HK2) mRNA was examined via RNA immunoprecipitation and actinomycin D assays.
[RESULTS] ARPC1B was significantly upregulated in GC tissues and cell lines, with elevated expression correlating positively with advanced tumor stage and pathological grade. ARPC1B depletion suppressed glycolytic activity (reduced ECAR, increased OCR, glucose consumption, lactate/ATP production), inhibited proliferation, migration, and invasion in vitro, and attenuated tumor growth and metastasis in vivo. Mechanistically, ARPC1B bound to IGF2BP3, impeding its degradation and ubiquitination, thereby enhancing HK2 mRNA stability. Consequently, ARPC1B increased HK2 protein expression, while HK2 overexpression rescued the anti-glycolytic and anti-tumorigenic effects of ARPC1B knockdown.
[CONCLUSION] ARPC1B drives GC progression by stabilizing HK2 mRNA through IGF2BP3 binding, thereby potentiating glycolytic reprogramming to facilitate tumor growth and metastasis. Targeting the ARPC1B-IGF2BP3-HK2 axis may represent a novel therapeutic strategy for GC.
[METHODS] ARPC1B expression in GC and its association with clinicopathological features were assessed using bioinformatics (TCGA, GEPIA), western blotting, and immunohistochemical staining. The functional impact of ARPC1B on glycolysis (ECAR, OCR, glucose uptake, lactate/ATP production) and tumorigenesis (proliferation, migration, invasion, in vivo xenografts) was evaluated following ARPC1B knockdown or overexpression. ARPC1B-IGF2BP3 interaction was validated by co-immunoprecipitation and confocal microscopy. IGF2BP3-dependent stabilization of hexokinase 2 (HK2) mRNA was examined via RNA immunoprecipitation and actinomycin D assays.
[RESULTS] ARPC1B was significantly upregulated in GC tissues and cell lines, with elevated expression correlating positively with advanced tumor stage and pathological grade. ARPC1B depletion suppressed glycolytic activity (reduced ECAR, increased OCR, glucose consumption, lactate/ATP production), inhibited proliferation, migration, and invasion in vitro, and attenuated tumor growth and metastasis in vivo. Mechanistically, ARPC1B bound to IGF2BP3, impeding its degradation and ubiquitination, thereby enhancing HK2 mRNA stability. Consequently, ARPC1B increased HK2 protein expression, while HK2 overexpression rescued the anti-glycolytic and anti-tumorigenic effects of ARPC1B knockdown.
[CONCLUSION] ARPC1B drives GC progression by stabilizing HK2 mRNA through IGF2BP3 binding, thereby potentiating glycolytic reprogramming to facilitate tumor growth and metastasis. Targeting the ARPC1B-IGF2BP3-HK2 axis may represent a novel therapeutic strategy for GC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- [Analysis of clinical characteristics and delays in diagnosis of the lymphoma of sinonasal cavities].
- Emerging perspectives on metabolic reprogramming in the microenvironment of ovarian cancer metastasis.
- PRR15 suppresses renal cell carcinoma progression via the NF-κB/FDX1 axis to induce cuproptosis and mitochondrial dysfunction.
- Microwave ablation combined with dendritic cells enhances CD8 T cell activation in rechallenged tumor mouse model.
- Are we reporting well enough? A systematic survey of missing data in patient-reported outcomes from non-small cell lung cancer randomized trials.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Copper-enriched zinc peroxides induced cuproptosis through concurrent metabolic and oxidative dysregulation for boosting immunotherapy in colorectal cancer.
- Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in -amplified gastric cancer.
- Association of preoperative frailty and prognostic nutritional index with postoperative delirium in elderly gastric cancer patients: A single-center observational study.
- Treating a single tumor deposits as two lymph node metastases can improve the accuracy of gastric cancer prognosis assessment.
- Mechanism of cancer-associated fibroblast-driven thyroid cancer dedifferentiation via the ZFP57-PKM2 axis-mediated lactate secretion and therapeutic intervention with resveratrol.